United States

People: Celgene Corp (CELG.O)

CELG.O on Nasdaq

19 Oct 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Alles, Mark 

Mr. Mark J. Alles serves as Chief Executive Officer, Director of the Celgene Corporation. Mr. Alles was our President and Chief Operating Officer from August 2014 through February 2016. Prior to that, Mr. Alles served as Executive Vice President and Global Head of Hematology and Oncology from December 2012 until July 2014, following his promotion to Executive Vice President and Chief Commercial Officer on February 15, 2012. Mr. Alles joined us in April 2004 and served as Vice President, Global Marketing until March 2009 when he became President of the Americas Region. Responsibility for commercial operations in Japan and the Asia Pacific Region was added in July 2011. Mr. Alles previously served as Vice President for the U.S. Oncology Business Unit of Aventis Pharmaceuticals and in other commercial sales and marketing management roles over an 11-year period with Aventis. After earning his B.S. degree from Lock Haven University of Pennsylvania and serving as a Captain in the United States Marine Corps, Mr. Alles began his 30-year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. Mr. Alles is a Trustee of The Healthcare Institute of New Jersey, a member of the Board of the Biotechnology Innovation Organization and a member of the Board of Gilda’s Club NYC, a not-for-profit organization helping the families of people living with cancer.

Basic Compensation

Total Annual Compensation, USD 4,752,240
Restricted Stock Awards, USD 4,257,760
Long-Term Incentive Plans, USD --
All Other, USD 3,182,420
Fiscal Year Total, USD 12,192,400

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 21,938 1,597,230.00
Name Fiscal Year Total

Robert Hugin


Scott Smith


Mark Alles


Peter Kellogg


Terrie Curran


Michael Pehl

As Of  30 Dec 2016